Penumbra Inc (NYSE:PEN) has received a consensus rating of “Buy” from the nine analysts that are currently covering the company, Marketbeat Ratings reports. Four equities research analysts have rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating on the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $156.60.

Several brokerages recently issued reports on PEN. Zacks Investment Research upgraded Penumbra from a “hold” rating to a “strong-buy” rating and set a $143.00 price target on the stock in a research note on Saturday, August 11th. BMO Capital Markets boosted their price target on Penumbra from $140.00 to $150.00 and gave the company a “market perform” rating in a research note on Thursday, August 9th. ValuEngine lowered Penumbra from a “buy” rating to a “hold” rating in a research note on Wednesday, August 8th. Wells Fargo & Co restated an “outperform” rating and set a $180.00 price target (up from $150.00) on shares of Penumbra in a research note on Thursday, May 31st. Finally, Canaccord Genuity boosted their price target on Penumbra from $125.00 to $165.00 and gave the company a “buy” rating in a research note on Wednesday, May 9th.

In other news, EVP Robert D. Evans sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, August 6th. The stock was sold at an average price of $150.16, for a total value of $1,501,600.00. Following the sale, the executive vice president now directly owns 15,667 shares in the company, valued at approximately $2,352,556.72. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Thomas Wilder sold 304 shares of the company’s stock in a transaction that occurred on Wednesday, July 11th. The shares were sold at an average price of $138.50, for a total value of $42,104.00. The disclosure for this sale can be found here. Over the last quarter, insiders sold 41,554 shares of company stock worth $5,952,954. Corporate insiders own 10.70% of the company’s stock.

Hedge funds have recently added to or reduced their stakes in the company. Goldman Sachs Group Inc. grew its stake in shares of Penumbra by 40.4% in the 4th quarter. Goldman Sachs Group Inc. now owns 16,420 shares of the company’s stock valued at $1,545,000 after purchasing an additional 4,726 shares during the period. Xact Kapitalforvaltning AB grew its stake in shares of Penumbra by 15.2% in the 2nd quarter. Xact Kapitalforvaltning AB now owns 4,558 shares of the company’s stock valued at $630,000 after purchasing an additional 600 shares during the period. Essex Investment Management Co. LLC bought a new stake in shares of Penumbra in the 2nd quarter valued at approximately $910,000. Swiss National Bank grew its stake in shares of Penumbra by 2.5% in the 1st quarter. Swiss National Bank now owns 50,100 shares of the company’s stock valued at $5,794,000 after purchasing an additional 1,200 shares during the period. Finally, Campbell & CO Investment Adviser LLC bought a new stake in shares of Penumbra in the 2nd quarter valued at approximately $387,000. Institutional investors own 75.06% of the company’s stock.

PEN traded down $2.60 on Wednesday, hitting $125.70. 336,749 shares of the stock traded hands, compared to its average volume of 331,140. Penumbra has a 52 week low of $81.50 and a 52 week high of $167.35. The firm has a market capitalization of $4.28 billion, a price-to-earnings ratio of -12,570.00, a P/E/G ratio of 23.46 and a beta of 0.15.

Penumbra (NYSE:PEN) last issued its quarterly earnings results on Tuesday, August 7th. The company reported $0.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.03 by $0.12. Penumbra had a return on equity of 2.78% and a net margin of 7.19%. The firm had revenue of $109.64 million for the quarter, compared to analyst estimates of $102.24 million. equities research analysts expect that Penumbra will post 0.27 earnings per share for the current fiscal year.

About Penumbra

Penumbra, Inc designs, develops, manufactures, and markets medical devices in the United States, Europe, Canada, Australia, Japan, and internationally. The company offers neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, DDC, and PX SLIM brands; aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the ACE and the 3D Revascularization Device brands.

Featured Story: Book Value Of Equity Per Share – BVPS Explained

Analyst Recommendations for Penumbra (NYSE:PEN)

Receive News & Ratings for Penumbra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Penumbra and related companies with MarketBeat.com's FREE daily email newsletter.